Mesenkia Therapeutics
Pre-clinicalMesenkia is a pre-clinical company developing the next-generation biological drug candidates, single domain antibodies (VHH) designed to treat the aggressive brain tumor glioblastoma.
Founded
2020
Focus
AntibodiesBiologics
About
Mesenkia is a pre-clinical company developing the next-generation biological drug candidates, single domain antibodies (VHH) designed to treat the aggressive brain tumor glioblastoma.
Company Info
TypePrivate
Founded2020
LocationStockholm, Sweden
StagePre-clinical
Contact
SIMILAR COMPANIES
Basic Genomics
Pre-clinical · Stockholm
2A Pharma
Phase 1 · Stockholm
Abliva
Pre-clinical · Lund
Affibody
Phase 1 · Solna
Alligator Bioscience
Phase 1 · Lund
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile